Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

 Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma

Shots:
  •  AZEDRA radio therapeutic indicated to treat adult and pediatric patients 12yrs with iobenguane scan positive 
  •  Has shown reduction rate in need of blood pressure medication and tumor size in patients for approved IV dose 555MBq/mL
  •  Approval was based on pivotal Ph 2 under SPA showing 17/68 (25%) 50% patients showed reduction in medication and tumor response of almost 53%

Click here to read full press release/ article | Ref: Progenics Pharmaceuticals | Image:  LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post